Cover Image
市場調查報告書

抗菌藥市場產品、開發平台分析

A Product and Pipeline Analysis of the Antibacterial Drugs Market

出版商 Frost & Sullivan 商品編碼 323423
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗菌藥市場產品、開發平台分析 A Product and Pipeline Analysis of the Antibacterial Drugs Market
出版日期: 2015年01月22日 內容資訊: 英文 122 Pages
簡介

本報告提供全球抗菌藥(抗生素)市場相關調查分析,以現在正在開發的抗生素為焦點,提供上市藥、產品與開發平台分析、法規方法等相關的系統性資訊。

第1章 摘要整理

第2章 簡介

第3章 抗菌藥的分類:各作用機制

  • 抗菌藥:認證核可藥、新藥的分類概要
  • 一般下處方的抗原的給藥計劃

第4章 抗菌藥市場:開發平台分析

  • 抗菌藥:開發中的產品的競爭情形
  • 抗菌藥:開發平台分析
  • 抗菌藥:開發平台概要

第5章 抗菌藥市場:主要的臨床里程碑

  • 抗菌藥市場:進展中/最近完成的主要的臨床試驗

第6章 抗菌藥市場:最近已批准後期開發平台藥物候補的產品開發動態即時看板系統

  • Tedizolid Phosphate
  • Dalbavancin (Dalvance)
  • Ceftolozane + Tazobactam
  • Oritavancin (Orbactiv)
  • Ceftazidime + Avibactam (CAZ - AVI)
  • Cadazolid
  • Carbavance
  • Delafloxacin
  • Eravacycline
  • Plazomicin
  • Solithromycin
  • Surotomycin

第7章 抗生素抗性:抗生素R&D的課題重大的未滿足需求

  • 抗生素抗性的通用機制
  • 抗生素R&D主要課題
  • 難治療的病原體/超強力的細菌,帶給製藥廠商嚴重的威脅
  • 開發平台的新抗生素,幫助克服藥物抗性

第8章 抗菌藥市場:主要的活動計劃

  • 抗菌藥的分類:FDA核准計劃
  • 抗菌藥:FDA核准計劃
  • 抗菌藥市場:主要的活動計劃

第9章 促進抗生素R&D的法規方法

  • 促進抗生素R&D的法規政策
  • GAIN法
  • GAIN法的實施
  • ADAPT法
  • IDSA的「10 x '20」計劃
  • 補充性的經濟獎勵策略:稅額扣抵
  • 補充性的經濟獎勵策略:聯邦政府的研究資金提供
  • PPP:歐洲的配合措施
  • PPP:BARDA

第10章 抗菌藥市場:值得注意的主要企業

  • 值得注意的主要企業

第11章 結論

第12章 附錄

第13章 關於FROST & SULLIVAN

目錄
Product Code: MABA-01-00-00-00

Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary-Key Findings
  • 2. Executive Summary-Key Findings (continued)
  • 3. Executive Summary-Key Findings (continued)
  • 4. Antibacterial Drugs Market-Game-changing Strategies
  • 5. Key Merger, Acquisition, and Partnership Assessment
  • 6. Key Merger, Acquisition, and Partnership Assessment (continued)
  • 7. Key Merger, Acquisition, and Partnership Assessment (continued)
  • 8. Key Merger, Acquisition, and Partnership Assessment (continued)
  • 9. Key Merger, Acquisition, and Partnership Assessment (continued)
  • 10. Methodology and Scope

2. INTRODUCTION

Introduction

  • 1. Introduction
  • 2. Introduction (continued)
  • 3. Market Overview-Segmentation

3. CLASSIFICATION OF ANTIBACTERIAL DRUGS BY MECHANISM OF ACTION

Classification of Antibacterial Drugs by Mechanism of Action

  • 1. Antibacterial Drugs-Approved and Novel Product Classes Synopsis
  • 2. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 3. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 4. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 5. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 6. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 7. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 8. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 9. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 10. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 11. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 12. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 13. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 14. Antibacterial Drugs-Approved and Novel Product Classes Synopsis (continued)
  • 15. Dosing Regimen of Commonly Prescribed Antigens
  • 16. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 17. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 18. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 19. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 20. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 21. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 22. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 23. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 24. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 25. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 26. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 27. Dosing Regimen of Commonly Prescribed Antigens (continued)
  • 28. Dosing Regimen of Commonly Prescribed Antigens (continued)

4. ANTIBACTERIAL DRUGS MARKET-PIPELINE ANALYSIS

Antibacterial Drugs Market-Pipeline Analysis

  • 1. Antibacterial Drugs-Competitive Landscape of Products in Development
  • 2. Antibacterial Drugs-Pipeline Analysis
  • 3. Antibacterial Drugs-Pipeline Synopsis
  • 4. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 5. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 6. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 7. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 8. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 9. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 10. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 11. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 12. Antibacterial Drugs-Pipeline Synopsis (continued)
  • 13. Antibacterial Drugs-Pipeline Synopsis (continued)

5. ANTIBACTERIAL DRUGS MARKET-MAJOR CLINICAL MILESTONES

Antibacterial Drugs Market-Major Clinical Milestones

  • 1. Antibacterial Drugs Market-Major Ongoing/Recently Completed Clinical Trials
  • 2. Antibacterial Drugs Market-Major Ongoing/Recently Completed Clinical Trials (continued)
  • 3. Antibacterial Drugs Market-Major Ongoing/Recently Completed Clinical Trials (continued)

6. ANTIBACTERIAL DRUGS MARKET-PRODUCT DASHBOARD OF RECENTLY APPROVED AND LATE-STAGE PIPELINE DRUG CANDIDATES

Antibacterial Drugs Market-Product Dashboard of Recently Approved and Late-stage Pipeline Drug Candidates

  • 1. Tedizolid Phosphate-Cubist Pharmaceuticals
  • 2. Dalbavancin (Dalvance™)-Durata Therapeutics
  • 3. Ceftolozane + Tazobactam-Cubist Pharmaceuticals
  • 4. Oritavancin (Orbactiv™)-The Medicines Company
  • 5. Ceftazidime + Avibactam (CAZ-AVI)-AstraZeneca
  • 6. Cadazolid-Actelion Pharmaceuticals
  • 7. Carbavance-Rempex Pharmaceuticals (The Medicines Company)
  • 8. Delafloxacin-Melinta Therapeutics
  • 9. Eravacycline-Tetraphase Pharmaceuticals
  • 10. Plazomicin-Achaogen
  • 11. Solithromycin-Cempra Pharmaceuticals
  • 12. Surotomycin-Cubist Pharmaceuticals

7. ANTIBIOTIC RESISTANCE-A CRITICAL UNMET NEED THAT POSES CHALLENGES TO ANTIBIOTIC R&D

Antibiotic Resistance-A Critical Unmet Need that Poses Challenges to Antibiotic R&D

  • 1. Common Mechanisms of Antibiotic Resistance
  • 2. Key Challenges to Antibiotic Research & Development
  • 3. Hard-to-treat Pathogens/Superbugs That Pose a Serious Threat to Drug Makers
  • 4. New Antibiotics in the Pipeline That Help Overcome Drug Resistance
  • 5. New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)
  • 6. New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)
  • 7. New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)
  • 8. New Antibiotics in the Pipeline That Help Overcome Drug Resistance (continued)

8. ANTIBACTERIAL DRUGS MARKET-TIMELINE OF KEY EVENTS

Antibacterial Drugs Market-Timeline of Key Events

  • 1. Antibacterial Drug Classes-FDA Approval Timeline
  • 2. Antibacterial Drug Classes-FDA Approval Timeline (continued)
  • 3. Antibacterial Drugs-FDA Approval Timeline
  • 4. Antibacterial Drugs Market-Timeline of Key Events
  • 5. Antibacterial Drugs Market-Timeline of Key Events (continued)

9. REGULATORY APPROACHES TO STIMULATE ANTIBIOTICS R&D

Regulatory Approaches to Stimulate Antibiotics R&D

  • 1. Regulatory Policies to Stimulate Antibiotics R&D
  • 2. Generating Antibiotics Incentives Now (GAIN) Act
  • 3. Implementation of the (GAIN) Act
  • 4. Antibiotic Development to Advance Patient Treatment Act (ADAPT): H.R. 3742
  • 5. IDSA's 10 x ‘20 Initiative
  • 6. Additional Economic Incentives-Tax Credits
  • 7. Additional Economic Incentives-Federal Research Funding
  • 8. Additional Economic Incentives-Federal Research Funding (continued)
  • 9. Additional Economic Incentives-Federal Research Funding (continued)
  • 10. PPPs-The European Effort
  • 11. PPPs-The European Effort (continued)
  • 12. PPPs-BARDA
  • 13. PPPs-BARDA (continued)

10. ANTIBACTERIAL DRUGS MARKET-KEY COMPANIES TO WATCH

Antibacterial Drugs Market-Key Companies to Watch

  • 1. Key Companies to Watch
  • 2. Key Companies to Watch (continued)

11. CONCLUSIONS

Conclusions

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

12. APPENDIX

Appendix

  • 1. List of Abbreviations

13. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top